Quick Answer
Allarity Therapeutics, Inc. reported Earnings Per Share Diluted of $10.26 (loss) per share for the year ending 2023.
- Allarity Therapeutics, Inc. showed an increase of +99.7% in Earnings Per Share Diluted from 2022 to 2023.
- This data is from Allarity Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 8, 2024.
- XBRL data for this metric is available from 2021 to 2023 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $1.08 (loss) per share | Q3 2021: $0.17 (loss) per share | Q1 2022: $19.64 (loss) per share | Q2 2022: $53.90 (loss) per share | Q3 2022: $934.29 (loss) per share | Q1 2023: $6,356.06 (loss) per share | Q2 2023: $525.53 (loss) per share | Q3 2023: $2.03 (loss) per share | Q1 2024: $22.14 (loss) per share | Q2 2024: $0.11 (loss) per share.
- Over the full 3 years of available data (2021 to 2023), Allarity Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 144.9%.
- Historical annual values: Fiscal year 2023: $10.26 (loss) per share | Fiscal year 2022: $3,093.42 (loss) per share | Fiscal year 2021: $4.19 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: